Quality of life of schizophrenic patients with or without depot neuroleptics

Introduction: Schizophrenia is a chronic mental illness that negatively affects the quality of life of the patient and his family. Primary therapy in the treatment of schizophrenia is antipsychotics. Aims of the study: The aim of this study was to compare the quality of life of schizophrenic patients treated with depot neuroleptics preparations and patients without depot neuroleptics. Patientes and Methods: The sample size included 64 patients aged 18-65 years divided into two groups: patients treated with depot neuroleptic preparations and the control group, patients not treated with depot neuroleptics. For the investigation we used history and socio-demographic data, body weight, blood pressure, as well as quality of life questionnaire [a combination of Lancashire and Mansa questionnaire) and short scale for psychiatric evaluation (BPRS). Results: The average age of the examinees was 44.19 ± 7.785 years (experimental group: 43.31 ± 6.879 and control 45.06 ± 8.617 years). Regarding the frequent changes in mood, there were no statistically significant differences between the groups, Hi = 0000, p <0.05. A statistically significant difference between the groups was found in the presence of hallucinations (c2 = 8.400, df = 3, p = 0.038), Conclusion: It was found that the quality of life of patients treated for schizophrenia does not significantly differ, regardless of whether depot preparations are used or not; this finding is in accordance with the reports made by other authors.